Scion Asset Management LLC Acquires Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB)

Scion Asset Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 633,959 shares of the company’s stock, valued at approximately $869,000. BioAtla accounts for 1.7% of Scion Asset Management LLC’s investment portfolio, making the stock its 10th largest position.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of BioAtla by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock valued at $7,221,000 after buying an additional 17,667 shares during the last quarter. AQR Capital Management LLC purchased a new stake in BioAtla during the 2nd quarter worth about $872,000. Massachusetts Financial Services Co. MA lifted its holdings in BioAtla by 2.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 541,199 shares of the company’s stock worth $741,000 after purchasing an additional 14,737 shares in the last quarter. Bank of Montreal Can lifted its holdings in BioAtla by 55.1% during the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock worth $554,000 after purchasing an additional 143,521 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in BioAtla by 28.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company’s stock worth $458,000 after purchasing an additional 73,598 shares in the last quarter. Institutional investors own 77.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of BioAtla in a report on Monday, September 16th.

BioAtla Stock Performance

Shares of BCAB opened at $1.63 on Friday. The stock’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $2.09. The stock has a market capitalization of $78.79 million, a price-to-earnings ratio of -0.65 and a beta of 1.06. BioAtla, Inc. has a 52-week low of $1.14 and a 52-week high of $4.02.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. During the same period in the previous year, the firm posted ($0.75) EPS. On average, research analysts forecast that BioAtla, Inc. will post -1.52 earnings per share for the current fiscal year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.